AR and cancer: Furthermore, targeting MAOA can disrupt its cross talk with the androgen receptor to restore enzalutamide sensitivity, block glucocorticoid receptor activity, and androgen receptor-dependent PCa cell growth, suggesting it as a potential strategy for immune checkpoint inhibition [91] to alleviate immune suppression and enhance T cell immunity-based cancer immunotherapy.